Urgency Therapy with Neuromodulation and C-Afferent Nerve Desensitization
1 Assignment
0 Petitions
Accused Products
Abstract
Systems (10), devices (16), and methods may be used for treating bladder dysfunction, such as urgency and pelvic pain. In one example, a method includes administering a pharmacological agent to a patient (14) in a dosage sufficient to desensitize a C-afferent nerve fiber of the patient. Additionally, the method includes delivering stimulation to activate a nerve fiber proximate to the C-afferent nerve fiber via an electrode (19A, 19B, 21A, 21B, 29A-29D) electrically coupled to an implantable medical device (16). In some examples, the nerve fiber may be different than the C-afferent nerve fiber, the stimulation of the nerve fiber may elicit an inhibitory physiological response related to voiding in the patient, and/or the stimulation substantially may not activate the C-afferent nerve fiber after desensitization of the nerve fiber via the administration of the pharmacological agent.
33 Citations
60 Claims
-
1-23. -23. (canceled)
-
24. A method comprising:
-
administering a pharmacological agent to a patient in a dosage sufficient to desensitize a C-afferent nerve fiber of the patient; and delivering electrical stimulation to activate a nerve fiber proximate to the C-afferent nerve fiber via an electrode electrically coupled to an implantable medical device, wherein the nerve fiber is different than the C-afferent nerve fiber, wherein the stimulation of the nerve fiber elicits an inhibitory physiological related to voiding in the patient, and wherein the stimulation substantially does not activate the C-afferent nerve fiber after desensitization of the nerve fiber via the administration of the pharmacological agent. - View Dependent Claims (25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)
-
-
36. A method comprising:
-
receiving via a control module of an implantable medical device an indication that a pharmacological agent has been administered in a dosage sufficient to desensitize a C-afferent nerve fiber to a patient in which the implantable medical device is implanted; selecting via the control module an electrical stimulation therapy program based on the received indication; and controlling via the control module a therapy delivery module to generate and deliver electrical stimulation therapy in accordance with the electrical stimulation therapy program, wherein the electrical stimulation therapy elicits an inhibitory physiological response related to voiding in the patient. - View Dependent Claims (37, 38, 39, 40, 41, 42, 43, 44)
-
-
45. A computer-readable medium comprising instructions that cause a processor to:
-
receive via an implantable medical device an indication that a pharmacological agent has been administered in a dosage sufficient to desensitize a C-afferent nerve fiber to a patient in which the implantable medical device is implanted; select an electrical stimulation therapy program based on the received indication; and control a therapy delivery module to generate and deliver electrical stimulation therapy in accordance with the electrical stimulation therapy program, wherein the electrical stimulation therapy elicits an inhibitory physiological response related to voiding in the patient. - View Dependent Claims (46, 47, 48, 49)
-
-
50. A system comprising:
-
means for administering a pharmacological agent to a patient in a dose sufficient to desensitize a C-afferent nerve fiber; and means for delivering electrical stimulation to activate a nerve fiber proximate to the C-afferent nerve fiber via an electrode electrically coupled to the means for delivering stimulation, wherein the nerve fiber is different than the C-afferent nerve fiber, wherein the stimulation of the nerve fiber elicits an inhibitory physiological related to voiding in the patient, and wherein the stimulation substantially does not activate the C-afferent nerve fiber after desensitization of the nerve fiber via the administration of the pharmacological agent. - View Dependent Claims (51, 52, 53, 54)
-
-
55. A system comprising:
-
means for receiving an indication that a pharmacological agent has been administered to a patient in a dosage sufficient to desensitize a C-afferent nerve fiber in the patient; means for selecting an electrical stimulation therapy program based on the received indication; and means for generating and delivering electrical stimulation therapy in accordance with the electrical stimulation therapy program, wherein the electrical stimulation therapy elicits an inhibitory physiological response related to voiding in the patient. - View Dependent Claims (56, 57, 58, 59, 60)
-
Specification